Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®

Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Benjamin Greener, Ye Zhang, Judd L. Walson
doi: https://doi.org/10.1101/2023.07.13.23292597

Article Information

doi 
https://doi.org/10.1101/2023.07.13.23292597
History 
  • July 13, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Yoshiaki Oda1,
  2. Yuji Kumagai2,
  3. Manabu Kanai1,
  4. Yasuhiro Iwama1,
  5. Iori Okura1,
  6. Takeshi Minamida1,
  7. Yukihiro Yagi1,
  8. Toru Kurosawa1,
  9. Benjamin Greener3,
  10. Ye Zhang3 and
  11. Judd L. Walson3
  1. 1Meiji Seika Pharma Co., Ltd., Chuo-ku, Tokyo, Japan
  2. 2Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan
  3. 3Arcturus Therapeutics, Inc., San Diego, CA, USA
  1. Corresponding author:
    Dr Judd L Walson Arcturus Therapeutics, Inc., 10628 Science Center Drive, Suite 250 San Diego, CA 92121 USA E-mail: judd.walson{at}arcturusrx.com Tel: +1-206-612-4571
Back to top
Posted July 13, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Benjamin Greener, Ye Zhang, Judd L. Walson
medRxiv 2023.07.13.23292597; doi: https://doi.org/10.1101/2023.07.13.23292597
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area